Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CervoMed Inc. (NASDAQ: CRVO) SEC filings, offering a detailed view of how the clinical-stage biotechnology company reports its operations, financial condition, and development plans for neflamapimod and related programs. As a NASDAQ Capital Market issuer, CervoMed files current reports on Form 8-K, annual reports on Form 10-K, and other documents that outline its progress in dementia with Lewy bodies (DLB) and other age-related brain disorders.
In recent Form 8-K filings, CervoMed has furnished press releases covering quarterly financial results, new clinical data from the Phase 2b RewinD-LB trial, and written feedback from the U.S. Food and Drug Administration on the design of its planned Phase 3 trial in DLB. These filings describe how the company plans to use endpoints such as change in Clinical Dementia Rating – Sum of Boxes (CDR-SB), enrichment strategies based on plasma ptau181, and biomarker assessments like glial fibrillary acidic protein (GFAP) to support a potential New Drug Application for neflamapimod.
Other 8-Ks document corporate governance events, including the appointment of new directors and executive officers, adoption of equity incentive plans, and stock option grants. Filings relating to the annual meeting of stockholders detail voting outcomes on director elections, auditor ratification, advisory votes on executive compensation, and approval of equity plans. Together, these documents provide a structured record of CervoMed’s governance, capital structure, and incentive arrangements.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new 8-Ks, 10-Qs, and 10-Ks as they are filed, while AI-generated highlights can point to important disclosures on clinical trial results, regulatory milestones, grant funding, and risk factors. Investors can also use the filings page to monitor how CervoMed describes its lead program, neflamapimod, and its broader strategy in age-related brain disorders over time.
CervoMed (NASDAQ:CRVO) filed an 8-K (Item 5.07) reporting voting results from its June 23 2025 Annual Meeting.
With 64.5% of shares represented, stockholders approved all four proposals: (1) election of seven directors; (2) ratification of RSM US LLP as 2025 auditor (5,571,505 for, 25,008 against); (3) advisory endorsement of 2024 executive pay (3,891,229 for, 33,195 against); and (4) adoption of the 2025 Equity Incentive Plan (3,798,568 for, 137,758 against). No other material changes, governance shifts, or financial impacts were disclosed.
Insider filing overview: CervoMed Inc. (CRVO) submitted a Form 4 reporting an equity award to newly elected director Frank Zavrl.
- Transaction date: 23 June 2025, reported on 25 June 2025.
- Instrument: Non-qualified stock option covering 8,100 shares of CervoMed common stock.
- Exercise price: $6.52 per share.
- Term: Option expires 23 June 2035 (10-year life).
- Vesting schedule: 1/12th of the option (≈675 shares) vests monthly on the last calendar day from 30 June 2025 through 31 May 2026, contingent on continued board service.
- Ownership impact: Following the grant, Zavrl beneficially owns 8,100 derivative securities; no open-market purchases or sales of common shares were reported.
The award was made under CervoMed’s 2025 Equity Incentive Plan in accordance with the company’s non-employee director compensation policy. No 10b5-1 trading plan was indicated, and no changes were disclosed to Zavrl’s direct or indirect ownership of non-derivative shares.
Investor takeaways: The filing represents routine onboarding compensation, aligning a new board member’s interests with shareholders. Dilution effect is immaterial at less than 0.1 % of the company’s outstanding shares (exact share count not provided in the filing). No immediate cash outflow or revenue impact arises, and the option strike price embeds future performance risk.
On 25-Jun-2025 CervoMed Inc. (CRVO) filed a Form 4 reporting that director and 10% owner Joshua S. Boger received a stock-option award on 23-Jun-2025. The grant covers 8,100 shares of common stock, exercisable at $6.52 per share under the 2025 Equity Incentive Plan. Vesting occurs in equal monthly 1/12th installments beginning 30-Jun-2025 and ending after one year, subject to Mr. Boger’s continued board service. No shares were bought or sold; the filing simply discloses a new derivative position. If exercised, the options would modestly increase the share count, but the size of the award is immaterial to the company’s overall capital structure. The transaction signals standard director compensation and better aligns the director’s economic interests with shareholders.
CervoMed Inc. (CRVO) Form 4 filing discloses an initial equity grant to newly elected non-employee director Dr. Marwan Sabbagh. On 06/23/2025 he received a stock option for 8,100 common shares at an exercise price of $6.52 under the 2025 Equity Incentive Plan. The option vests in equal 1/12-increments on the last day of each month from 06/30/2025 through 05/31/2026, contingent on continued board service, and expires on 06/23/2035. No common shares were purchased or sold, and total derivative holdings now stand at 8,100 options. The transaction is routine director compensation with negligible dilution and no immediate impact on CervoMed’s financial position.
CervoMed Inc. (CRVO) – Form 4 insider filing
On June 23, 2025 newly elected director Jeffrey V. Poulton received a non-qualified stock option for 8,100 common shares under the company’s 2025 Equity Incentive Plan. The option carries an exercise price of $6.52 and a ten-year term expiring June 23, 2035. Vesting occurs monthly in equal 1/12-increments beginning June 30, 2025 and completes after one year, contingent on continued board service.
No shares were bought or sold in the open market; the filing reflects an equity award customary for non-employee directors. Following the grant, Mr. Poulton beneficially owns 8,100 derivative securities and no change is reported for non-derivative holdings. The transaction was reported on June 25, 2025 and is categorized under Code “A” (grant) in Table II.
From an investor perspective, the filing is routine, modest in size and unlikely to materially impact the share count or near-term valuation, but it does strengthen director equity alignment.
CervoMed Director Jane H. Hollingsworth received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments
- Vesting begins June 30, 2025, subject to continued service
The stock options were granted under the company's 2025 Equity Incentive Plan in accordance with their non-employee director compensation policy. The Form 4 was filed by William R. Elder as attorney-in-fact for Hollingsworth.
CervoMed Director and 10% owner Sylvie Gregoire received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments starting June 30, 2025
- Grant made under the company's 2025 Equity Incentive Plan per non-employee director compensation policy
The options are subject to continued service through applicable vesting dates. The filing was signed by William R. Elder as attorney-in-fact for Gregoire on June 25, 2025.